lncRNA PVT1 in the Pathogenesis and Clinical Management of Renal Cell Carcinoma
| Authors | |
|---|---|
| Year of publication | 2021 |
| Type | Article in Periodical |
| Magazine / Source | Biomolecules |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.mdpi.com/2218-273X/11/5/664 |
| Doi | http://dx.doi.org/10.3390/biom11050664 |
| Keywords | biomarker; prognosis; diagnosis; long non-coding RNA; tumorigenesis |
| Description | LncRNA PVT1 (plasmacytoma variant translocation 1) has become a staple of the lncRNA profile in patients with renal cell carcinoma (RCC). Common dysregulation in renal tumors outlines the essential role of PVT1 in the development of RCC. There is already a plethora of publications trying to uncover the cellular mechanisms of PVT1-mediated regulation and its potential exploitation in management of RCC. In this review, we summarize the literature focused on PVT1 in RCC and aim to synthesize the current knowledge on its role in the cells of the kidney. Further, we provide an overview of the lncRNA profiling studies that have identified a more or less significant association of PVT1 with the clinical behavior of RCC. Based on our search, we analyzed the 17 scientific papers discussed in this review that provide robust support for the indispensable role of PVT1 in RCC development and future personalized therapy. |
| Related projects: |